Nabriva Therapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company engaged in the research, development and commercialization of anti-infective agents to treat serious infections. Co. has approval from the U.S. Food and Drug Administration for XENLETA for the treatment of adults with community-acquired bacterial pneumonia. XENLETA is an oral and intravenous treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. Co.'s CONTEPO is a potentially epoxide antibiotic for intravenous use in the U.S. for complicated urinary tract infections. Co. may develop XENLETA and CONTEPO for additional indications. The NBRV stock yearly return is shown above.
The yearly return on the NBRV stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NBRV annual return calculation with any dividends reinvested as applicable (on ex-dates).
|